"MapQuant Dx(TM) Genomic Grade demonstrates our commitment to address clinicians' needs by translating the genomic profile of each tumor into reliable, intelligible and decisive information for pathologists, oncologists and patients," said Vincent Fert, President and CEO of Ipsogen.
About MapQuant Dx(TM) Genomic Grade
MapQuant Dx(TM) Genomic Grade measures the Genomic Grade index, a gene expression index discovered by oncology researchers at the Bordet Institute (Brussels, Belgium) and ISREC (Lausanne, Switzerland), two leading European cancer research institutes. In their seminal paper published in 2006 in the Journal of the National Cancer Institute (1), Pr. Sotiriou & colleagues showed that the grade, as measured today and since 1890 by histological examination of breast tumor sections under a microscope, could not describe the proliferation ability of 30 to 60 % of tumors. By contrast, the Genomic Grade index could capture proliferation in most tumors and showed superior prognostic and classification value over conventional grading methods. These findings have been validated in more than 1,100 patients, including a second study published last year in the Journal of Clinical Oncology (2). In 2008, 3 studies from the MD Anderson Cancer Center (MDACC) validated that high Genomic Grade index was predictive for benefit from chemotherapy (3).
MapQuant Dx(TM) Genomic Grade is based on Affymetrix technology.
"Affymetrix is partnering with the world's leading diagnostic companies
like Ipsogen to bring about new diagnostic tests that can provide more
efficient and complete methods to better diagnose, classify and manage
complex diseases like
|SOURCE Ipsogen SA|
Copyright©2008 PR Newswire.
All rights reserved